HIV-1 sensitivity to zidovudine and clinical outcome in children.

PubWeight™: 2.93‹?› | Rank: Top 1%

🔗 View Article (PMID 1345951)

Published in Lancet on January 04, 1992

Authors

G Tudor-Williams1, M H St Clair, R E McKinney, M Maha, E Walter, S Santacroce, M Mintz, K O'Donnell, T Rudoll, C L Vavro

Author Affiliations

1: Department of Pediatrics, Duke University Medical Center, Durham, North Carolina.

Articles citing this

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother (1993) 2.68

Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol (1993) 1.78

Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol (1995) 1.57

Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother (1992) 1.22

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol (1996) 1.18

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother (1993) 1.14

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine. Antimicrob Agents Chemother (1997) 1.12

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.09

Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob Agents Chemother (1993) 0.98

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother (1994) 0.95

A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother (1997) 0.94

Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol (1994) 0.92

Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Res (1993) 0.92

Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol (1994) 0.90

Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob Agents Chemother (1994) 0.84

HIV-1 sensitivity to zidovudine and clinical outcome. Lancet (1992) 0.75

HIV-1 sensitivity to zidovudine and clinical outcome. Lancet (1992) 0.75

Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (1997) 0.75

Articles by these authors

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48

Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol (1979) 4.53

Compensation to a department of medicine and its faculty members for the teaching of medical students and house staff. N Engl J Med (1996) 4.49

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA (1999) 2.79

Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol (2008) 2.57

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31

Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med (2000) 2.31

Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem (1981) 2.29

Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med (1994) 2.29

The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28

Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother (1981) 2.21

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16

Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis (1987) 2.06

Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med (1995) 2.04

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother (1997) 1.88

Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem (1984) 1.83

Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology (1994) 1.80

Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities. J Virol (1981) 1.74

Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem (1988) 1.69

Human immunodeficiency virus transmission by child sexual abuse. Am J Dis Child (1991) 1.69

Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U. Antimicrob Agents Chemother (1984) 1.67

Transjugular intrahepatic portosystemic stent-shunt (TIPS) in the treatment of Budd-Chiari syndrome. J Hepatol (1993) 1.63

Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest (2000) 1.62

When to suspect fungal infection in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics (2000) 1.58

Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med (1995) 1.58

Improved neurodevelopmental outcomes following long-term high-dose oral acyclovir therapy in infants with central nervous system and disseminated herpes simplex disease. J Perinatol (2005) 1.57

Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis (1982) 1.56

Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med (1997) 1.56

Risks and prophylaxis in laparoscopy: a survey of 100,000 cases. J Reprod Med (1977) 1.54

Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint. EMBO J (1991) 1.52

Pediatric acquired immunodeficiency syndrome. Barriers to recognizing the role of child sexual abuse. Am J Dis Child (1993) 1.49

Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis (1999) 1.45

Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother (1991) 1.45

Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release (2001) 1.45

Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg (1997) 1.44

Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol (1998) 1.44

Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood (1990) 1.42

Identifying human immunodeficiency virus infection at birth: application of polymerase chain reaction to Guthrie cards. J Pediatr (1993) 1.41

Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother (1980) 1.41

Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest (2001) 1.40

Images in cardiovascular medicine. Idiopathic hypereosinophilic vasculitis. Circulation (1995) 1.39

FDA and Panalba: a conflict of commercial, therapeutic goals? Science (1969) 1.38

Changes in behaviors of inpatients after a ban on the sale of caffeinated drinks. Hosp Community Psychiatry (1991) 1.38

Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes. Genes Immun (2005) 1.37

Effects of 3'-azido-3'-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun (1988) 1.30

Two S-phase checkpoint systems, one involving the function of both BIME and Tyr15 phosphorylation of p34cdc2, inhibit NIMA and prevent premature mitosis. EMBO J (1996) 1.27

Chromosome complement of the fungal plant pathogen Fusarium graminearum based on genetic and physical mapping and cytological observations. Genetics (2005) 1.26

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother (1994) 1.25

Phylogeny of the yeast genera Hanseniaspora (anamorph Kloeckera), Dekkera (anamorph Brettanomyces), and Eeniella as inferred from partial 26S ribosomal DNA nucleotide sequences. Int J Syst Bacteriol (1994) 1.25

Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis (1980) 1.22

Reduced in vivo mutagenesis by mutant herpes simplex DNA polymerase involves improved nucleotide selection. Proc Natl Acad Sci U S A (1985) 1.21

Bacteremia, central catheters, and neonates: when to pull the line. Pediatrics (2001) 1.21

Gene Genealogies and AFLP Analyses in the Fusarium oxysporum Complex Identify Monophyletic and Nonmonophyletic Formae Speciales Causing Wilt and Rot Disease. Phytopathology (2000) 1.18

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17

Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol (2001) 1.15

Pediatric HIV infection in Elista, Russia: interventional strategies. Am J Public Health (1995) 1.15

Spot-blot hybridization assay for the detection of hepatitis B virus DNA in serum: factors determining its sensitivity and specificity. Hepatology (1987) 1.15

Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother (1987) 1.13

Candidal mycetoma in the neonatal kidney. Pediatrics (1999) 1.13

Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol (1997) 1.12

Isolation of a functional homolog of the cell cycle-specific NIMA protein kinase of Aspergillus nidulans and functional analysis of conserved residues. J Biol Chem (1995) 1.11

Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. Virology (1988) 1.09

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol (1990) 1.09

Ultrasound diagnosis of fetal anomalies associated with in utero cocaine exposure: further support for cocaine-induced vascular disruption teratogenesis. Fetal Diagn Ther (1994) 1.08

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol (1996) 1.08

Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Thromb Haemost (1979) 1.08

Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition. Proc Natl Acad Sci U S A (1985) 1.08

Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Virology (1991) 1.08

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J (1993) 1.07

HIV-1 infected women and prenatal care utilization: barriers and facilitators. AIDS Patient Care STDS (2000) 1.06

[Risk and prevention of complications in gynecologic laparoscopy. Survey of 100,000 cases]. J Gynecol Obstet Biol Reprod (Paris) (1976) 1.06

Active site cavity of herpesvirus proteases revealed by the crystal structure of herpes simplex virus protease/inhibitor complex. Biochemistry (1997) 1.04

Stress-induced cytokine responses and central adiposity in young women. Int J Obes (Lond) (2007) 1.02

Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther (2007) 1.02

Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol (1981) 1.02

Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. Am J Kidney Dis (1988) 1.01

Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis (2000) 1.01

Molecular and cellular mediators of interleukin-1-dependent acute inflammatory arthritis. Arthritis Rheum (2001) 1.00

Metabolites of naloxone in human urine. J Pharm Sci (1971) 0.99

Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98

Systematic Numbering of Vegetative Compatibility Groups in the Plant Pathogenic Fungus Fusarium oxysporum. Phytopathology (1998) 0.98

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics (1999) 0.96

Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder. Neurology (2008) 0.96

Fusarium euwallaceae sp. nov.--a symbiotic fungus of Euwallacea sp., an invasive ambrosia beetle in Israel and California. Mycologia (2013) 0.96

Involvement of the amygdala in classical conditioning of eyeblink response in the rat. Brain Res (2001) 0.96

Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1. Am J Med (1982) 0.96

Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci (1987) 0.96

Penicillin-induced coagulation disorder. Lancet (1976) 0.96

Surface modification of PLGA microspheres. J Biomed Mater Res A (2003) 0.95

Platelet hyperaggregability as a consequence of the nephrotic syndrome. Thromb Res (1981) 0.94

Utility of an HIV-1 RNA assay in the diagnosis of acute retroviral syndrome. South Med J (2000) 0.94

Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat (2005) 0.93

In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med (1992) 0.93

Fathers and mothers developing skills in managing children's long-term medical conditions: how do their qualitative accounts compare? Child Care Health Dev (2011) 0.93

Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. Pediatr Infect Dis J (1996) 0.93

Evolution of Fusarium oxysporum f. sp. vasinfectum Races Inferred from Multigene Genealogies. Phytopathology (2001) 0.93

Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics (1999) 0.92